Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study

Jordan, S., Steer, C., DeFazio, A., Quinn, M., Obermair, A., Friedlander, M., Francis, J., O'Brien, S., Goss, G., Wyld, D. and Webb, P. (2013) Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study. Gynecologic Oncology, 129 2: 310-317. doi:10.1016/j.ygyno.2013.02.007


Author Jordan, S.
Steer, C.
DeFazio, A.
Quinn, M.
Obermair, A.
Friedlander, M.
Francis, J.
O'Brien, S.
Goss, G.
Wyld, D.
Webb, P.
Title Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study
Journal name Gynecologic Oncology   Check publisher's open access policy
ISSN 0090-8258
1095-6859
Publication date 2013
Year available 2013
Sub-type Article (original research)
DOI 10.1016/j.ygyno.2013.02.007
Volume 129
Issue 2
Start page 310
End page 317
Total pages 8
Place of publication Maryland Heights, MO United States
Publisher Academic Press
Language eng
Abstract Objective: Ovarian cancer five-year survival is poor at < 40%. In the absence of effective screening or new treatments, ensuring all women receive optimal treatment is one avenue to improve survival. There is little population-based information regarding the primary chemotherapy treatment that women with epithelial ovarian cancer receive. This information is essential to identify potential gaps in care. Methods: Cancer registries identified all women diagnosed with invasive epithelial ovarian cancer in Australia in 2005 (n = 1192). Histopathology, chemotherapy and comorbidity information was abstracted from medical records. Multivariable logistic regression was used to identify factors associated with chemotherapy commencement, regimen, and completion. Results: Women > 70 years (p < 0.0001), those with high-grade, stage IA/IB cancers (vs. stages IC-IV, p = 0.003) and those with mucinous cancers (p = 0.0002) were less likely to start chemotherapy. Most treated women received platinum-based drugs (97%), but only 68% received combination carboplatin-paclitaxel and only half completed six cycles without treatment modification/delay. Approximately 19% received single-agent carboplatin: mostly those aged > 70 (p < 0.0001) and/or with co-morbidities (p < 0.0001). Age was the strongest predictor of completing six cycles of combination therapy. Conclusions: For specific patient groups, particularly older women, there is notable variation from standard treatment. Understanding how treatment variations affect survival and determining optimal regimens for these groups are research priorities.
Keyword Chemotherapy
Older women
Ovarian cancer
Patterns of care
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 28 Aug 2015, 19:46:11 EST by System User on behalf of Medicine - Royal Brisbane and Women's Hospital